SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-020882
Filing Date
2024-03-08
Accepted
2024-03-08 08:38:56
Documents
16
Period of Report
2024-03-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0201409-8k_allarity.htm   iXBRL 8-K 28216
2 PRESS RELEASE DATED MARCH 8, 2024 ea020140901ex99-1_allarity.htm EX-99.1 127470
3 GRAPHIC ex99-1_001.jpg GRAPHIC 12876
  Complete submission text file 0001213900-24-020882.txt   362063

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE allr-20240308.xsd EX-101.SCH 3015
5 XBRL LABEL FILE allr-20240308_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE allr-20240308_pre.xml EX-101.PRE 22359
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0201409-8k_allarity_htm.xml XML 3726
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 24732441
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)